Dr. Thomas P. Davis is Professor of Medical Pharmacology in the College of Medicine and Professor of Pharmacology and Toxicology in the College of Pharmacy, at the University of Arizona- Tucson Campus. He received his bachelor’s degree in biology from Loyola University, his M.Sc. in exercise physiology in Dr. David Bruce Dills’ Desert Research Institute at the University of Nevada and his Ph.D. in physiologyiochemistry in Dr. Charles Gehrke’s lab at the University of Missouri. He was hired by the late Dr. George Rathmann to carry out award winning, postdoctoral training at Abbott Laboratories as a development chemist and founder of the analytical confirmation laboratory in the therapy monitoring venture grou(TDx) before joining the University of Arizona faculty in November 1980. Dr. Davis’ research interests include novel and award-winning studies of the molecular, biochemical, and pathophysiological mechanisms associated with maintenance and disruption of the blood-brain barrier endothelial cell tight junction proteins and neurovascular unit that leads to CNS drug delivery challenges, in several disease states associated with hypoxia, stroke and acute pain states. He has studied the challenges of drug delivery across the blood-brain barrier with continuous basic science RO1 research grant awards, as a PI, from the N.I.H. from 1985 to 2025. His pioneering, award winning program of research has published 260 well cited, high impact, peer-reviewed research articles with a H index of 74, a i10 index of 196 and 20,000 citations. He has served as an invited chartered member on five different N.I.H. brain disorders clinical neurosciences study sections, including N.S.F. MRC and V.A. study sections. Dr. Davis was awarded a special citation from the University of Arizona Chair of the Faculty for his extraordinary and expert service to the University in 2001, a distinguished award citation from Loyola-Marymount University College of Science and Engineering for inclusion on the Alumni Wall of Fame in 2003 and awarded The Founders Day Award and lecture from The University of Arizona College of Medicine in 2011. Dr. Davis continues his research program today as the P.I. of a NIH/NIDA RO1 drug delivery grant to 2025. His lab discovered specific BBB drug transporters such as Pgand OATP altered by stroke and acute pain states which can be targeted to enhance drug delivery. He also studies the effect of hypoxia, stroke, and acute pain on endothelial cell tight junction protein integrity, leak, permeability and Pgp transporter trafficking from the nucleus to the vascular lumen at the BBB. His lab has now shown that short-term hypoxia and MCAO/Stroke leads to significant alterations in brain permeability and OATP PgP BCRP transporter expression that can be reversed by specific antagonists, antioxidants, and OTC drugs. This work has significant consequences to the treatment of stroke demonstrating that the OATP1a2 transporter is central to neuroprotectant atorvastatin drug delivery in treating stroke. . Web Site http:www.davislab.med.arizona.edu/